Indication
Relapsing remitting multiple sclerosis
Relapsing-remitting multiple sclerosis is a chronic, immune-mediated neurodegenerative disorder of the central nervous system and represents the most common clinical phenotype of multiple sclerosis. Read more about Relapsing remitting multiple sclerosis
2 drugs 1 manufacturers
Drugs that treat it
Common Relapsing remitting multiple sclerosis therapies.
OCREVUS ZUNOVO (ocrelizumab-hyaluronidase-ocsq)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRelapsing-remitting multiple sclerosis is a chronic, immune-mediated neurodegenerative disorder of the central nervous system and represents the most common clinical phenotype of multiple sclerosis.
Primarily affecting young adults, particularly females, it is driven pathologically by autoimmune inflammatory attacks targeting the protective myelin sheath and underlying axons within the brain, optic nerves, and spinal cord.
Clinically, it is defined by discrete episodes of acute or subacute neurologic dysfunction—termed relapses or exacerbations—followed by periods of partial or complete symptom recovery and relative disease stability during remission.
Over time, repeated attacks and incomplete remissions can cause cumulative axonal injury, leading to progressive neurological impairment.
- medlineplus.gov
Relapsing-remitting multiple sclerosis is a chronic, immune-mediated neurodegenerative disorder of the central nervous system and represents the most common clinical phenotype of multiple sclerosis
- nih.gov
Relapsing-remitting multiple sclerosis is a chronic, immune-mediated neurodegenerative disorder of the central nervous system and represents the most common clinical phenotype of multiple sclerosis
- nationalmssociety.org
Relapsing-remitting multiple sclerosis is a chronic, immune-mediated neurodegenerative disorder of the central nervous system and represents the most common clinical phenotype of multiple sclerosis Primarily affecting young adults, particularly females, it is driven pathologically by autoimmune inflammatory attacks targeting the protective myelin sheath and underlying axons within the brain, optic nerves, and spinal cord Clinically, it is defined by discrete episodes of acute or subacute neurolo...
- hopkinsmedicine.org
Primarily affecting young adults, particularly females, it is driven pathologically by autoimmune inflammatory attacks targeting the protective myelin sheath and underlying axons within the brain, optic nerves, and spinal cord Over time, repeated attacks and incomplete remissions can cause cumulative axonal injury, leading to progressive neurological impairment
- avonex.com
Primarily affecting young adults, particularly females, it is driven pathologically by autoimmune inflammatory attacks targeting the protective myelin sheath and underlying axons within the brain, optic nerves, and spinal cord Clinically, it is defined by discrete episodes of acute or subacute neurologic dysfunction—termed relapses or exacerbations—followed by periods of partial or complete symptom recovery and relative disease stability during remission
- mssociety.org.uk
Over time, repeated attacks and incomplete remissions can cause cumulative axonal injury, leading to progressive neurological impairment
Personalize your experience
Follow Relapsing remitting multiple sclerosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.